Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting

R. Hofland (Utrecht, Netherlands), B. Aalbers (Utrecht, Netherlands), I. Bronsveld (Utrecht, Netherlands), M. Kruijswijk (Utrecht, Netherlands), S. Schotman (Utrecht, Netherlands), H. Heijerman (Utrecht, Netherlands)

Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Session: Clinical monitoring and new therapies for cystic fibrosis
Session type: E-poster session
Number: 363
Disease area: Paediatric lung diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
R. Hofland (Utrecht, Netherlands), B. Aalbers (Utrecht, Netherlands), I. Bronsveld (Utrecht, Netherlands), M. Kruijswijk (Utrecht, Netherlands), S. Schotman (Utrecht, Netherlands), H. Heijerman (Utrecht, Netherlands). Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting. 363

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: